Related references
Note: Only part of the references are listed.Proteasome inhibitors and cardiac cell growth
Nadia Hedhli et al.
CARDIOVASCULAR RESEARCH (2010)
Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms
Giulia Mearini et al.
CARDIOVASCULAR RESEARCH (2010)
Build it up-Tear it down: protein quality control in the cardiac sarcomere
Monte S. Willis et al.
CARDIOVASCULAR RESEARCH (2009)
Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction
Sabine J. van Dijk et al.
CIRCULATION (2009)
Nonsense-Mediated mRNA Decay and Ubiquitin-Proteasome System Regulate Cardiac Myosin-Binding Protein C Mutant Levels in Cardiomyopathic Mice
Nicolas Vignier et al.
CIRCULATION RESEARCH (2009)
Familial hypertrophic cardiomyopathy: Basic concepts and future molecular diagnostics
Jessica E. Rodriguez et al.
CLINICAL BIOCHEMISTRY (2009)
A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy
Felix W. Friedrich et al.
EUROPEAN HEART JOURNAL (2009)
Hypertrophic cardiomyopathy: current understanding and treatment objectives
G. S. Soor et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Proteasome inhibition promotes regression of left ventricular hypertrophy
William E. Stansfield et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload
Nadia Hedhli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Cardiac myosin-binding protein C modulates the tuning of the molecular motor in the heart
Yves Lecarpentier et al.
BIOPHYSICAL JOURNAL (2008)
Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy
Emma J. Birks et al.
CARDIOVASCULAR RESEARCH (2008)
Letter by Csont and Ferdinandy regarding article, Biglycan Is Required For Adaptive Remodeling After Myocardial Infarction
Tamas Csont et al.
CIRCULATION (2008)
Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice
L. M. T. Eijssen et al.
GENOMICS (2008)
Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system
Silke Meiners et al.
HYPERTENSION (2008)
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib
Abdullah Hacihanefioglu et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Ubipuitin-Proteasome System Impairment Caused by a Missense Cardiac Myosin-binding Protein C Mutation and Associated with Cardiac Dysfunction in Hypertrophic Cardiomyopathy
Udin Bahrudin et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Introducing sense into nonsense in treatments of human genetic diseases
Liat Linde et al.
TRENDS IN GENETICS (2008)
Incomplete nonsense-mediated decay of mutant lamin A/C mRNA provokes dilated cardiomyopathy and ventricular tachycardia
Stephanie K. Geiger et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22
Nadia Hedhli et al.
CARDIOVASCULAR RESEARCH (2008)
Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases
Perry Elliott et al.
EUROPEAN HEART JOURNAL (2008)
Cardiac myosin-binding protein c is required for complete relaxation in intact myocytes
Lutz Pohlmann et al.
CIRCULATION RESEARCH (2007)
Unexpected cardiotoxicity in haematological bortezomib treated patients
Enrico Orciuolo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy
Barry J. Maron et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome
Qiuming Gong et al.
CIRCULATION (2007)
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers
Samit Hirawat et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Radial displacement of myosin cross-bridges in mouse myocardium due to ablation of myosin binding protein-C
Brett A. Colson et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
The highways and byways of mRNA decay
Nicole L. Garneau et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Modulating the expression of disease genes with RNA-Based therapy
Matthew Wood et al.
PLOS GENETICS (2007)
Proteasome-mediated degradation of integral inner nuclear membrane protein emerin in fibroblasts lacking A-type lamins
Antoine Muchir et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
The genetic bases of cardiomyopathies
Pascale Richard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Nonsense-mediated mRNA decay: target genes and functional diversification of effectors
Jan Rehwinkel et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium. is accompanied by changes in specific E3 ligases
Sundaravadivel Balasubramanian et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts
Fusako Usuki et al.
MOLECULAR THERAPY (2006)
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
Jens Voortman et al.
BMC CANCER (2006)
Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart
P Razeghi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes
JB Liu et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice
O Tsukamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts
Jinbao Liu et al.
FASEB JOURNAL (2006)
Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice
O Cazorla et al.
CARDIOVASCULAR RESEARCH (2006)
The ubiquitin proteolytic system - From a vague idea, through basic mechanisms, and onto human diseases and drug targeting
A Ciechanover
NEUROLOGY (2006)
The ubiquitin-proteasome system: Focus on the heart
Oliver Zolk et al.
CARDIOVASCULAR RESEARCH (2006)
Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake
QH Chen et al.
CIRCULATION RESEARCH (2005)
Dilated-hypokinetic evolution of hypertrophic cardiomyopathy - Prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients
E Biagini et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy
A Sanbe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants
A Sarikas et al.
CARDIOVASCULAR RESEARCH (2005)
Genetic factors in aminoglycoside toxicity
N Fischel-Ghodsian
PHARMACOGENOMICS (2005)
Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties
DI Keller et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2004)
Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice
L Carrier et al.
CARDIOVASCULAR RESEARCH (2004)
Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
E Kerem
CURRENT OPINION IN PULMONARY MEDICINE (2004)
Biomolecular interactions between human recombinant β-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy
J Flavigny et al.
CARDIOVASCULAR RESEARCH (2003)
Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins
G Bonuccelli et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Hypertrophic cardiomyopathy - Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy
P Richard et al.
CIRCULATION (2003)
Hyperubiquitination of proteins in dilated cardiomyopathy
J Weekes et al.
PROTEOMICS (2003)
Genetic testing and genetic counselling in hypertrophic cardiomyopathy:: the French experience
P Charron et al.
JOURNAL OF MEDICAL GENETICS (2002)
Hypertrophic cardiomyopathy - A systematic review
BJ Maron
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy
J Deinum et al.
HYPERTENSION (2001)
Expression of R120G-αB-crystallin causes aberrant desmin and αB-crystallin aggregation and cardiomyopathy in mice
XJ Wang et al.
CIRCULATION RESEARCH (2001)
Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.
P Spirito et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance
JA Moolman et al.
CIRCULATION (2000)
Share Paper
